Treatment of patients with posttransplant lymphoproliferative disorder (PTLD) with a sequential treatment consisting of anti-CD20 antibody rituximab and CHOP + GCSF chemotherapy.

Trial Profile

Treatment of patients with posttransplant lymphoproliferative disorder (PTLD) with a sequential treatment consisting of anti-CD20 antibody rituximab and CHOP + GCSF chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Post-transplant lymphoproliferative disorder
  • Focus Therapeutic Use
  • Acronyms PTLD-1; PTLD-1/3
  • Most Recent Events

    • 06 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 06 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 22 Dec 2016 Planned number of patients changed from 150 to 225.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top